Business Context and Reporting Period
PDS Biotechnology Corp (PDSB) filed this Form 8-K on June 2, 2026, regarding a corporate governance event related to its listing status on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance status.
Material Changes
The Company previously received a deficiency letter on February 25, 2026, stating that its common stock closing bid price had been below the $1.00 minimum requirement for 30 consecutive business days. On June 2, 2026, the Company received written notice from Nasdaq confirming it has regained compliance with the Minimum Bid Price Requirement and that the matter is closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks. The primary risk addressed was the potential delisting due to low stock price, which has been resolved as of the report date.
Investor Verification Checklist
- Verify the current trading price of PDSB to ensure it remains above the $1.00 threshold.
- Confirm the Company's continued compliance with other Nasdaq listing requirements.
- Review subsequent filings for any new deficiency notices or operational updates.